Payment overview · 2025
General Payments
$11,648.73
18 reported records · 2 companies
Healthcare provider profile · identity verified
Jay R Kostman, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · PHILADELPHIA, PA · NPI 1720014962
Verified facts
What the public records show
CMS Open Payments records show Jay R Kostman, MD received $11,648.73 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Descovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $6,665.89 | 57.2% | 15 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $4,982.84 | 42.8% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,500.00 | 2 |
| Consulting Fee | $4,940.00 | 1 |
| Travel and Lodging | $1,007.78 | 3 |
| Food and Beverage | $200.95 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $6,665.89 | 15 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $4,940.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
149 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 158 | 26 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 149 | 16 |
| Tivicay | Dolutegravir Sodium | 133 | 14 |
| Lisinopril | Lisinopril | 130 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 20 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 120 | 12 |
| Valacyclovir | Valacyclovir Hcl | 108 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 16 |
| Gabapentin | Gabapentin | 102 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 15 |
| Montelukast Sodium | Montelukast Sodium | 87 | suppressed |
| Testosterone | Testosterone | 86 | 11 |
| Isentress | Raltegravir Potassium | 81 | suppressed |
| Losartan Potassium | Losartan Potassium | 79 | 15 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 79 | suppressed |
| Lorazepam | Lorazepam | 76 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 76 | 11 |
| Chlorthalidone | Chlorthalidone | 70 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | suppressed |
| Darunavir | Darunavir | 59 | suppressed |
| Metformin Hcl | Metformin Hcl | 59 | 12 |
| Furosemide | Furosemide | 56 | suppressed |
| Jardiance | Empagliflozin | 56 | suppressed |
| Ritonavir | Ritonavir | 53 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Carvedilol | Carvedilol | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 48 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 48 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 48 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 13 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 43 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Omeprazole | Omeprazole | 39 | suppressed |
| Etravirine | Etravirine | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 23 | suppressed |
| Prezista | Darunavir | 23 | suppressed |
| Abacavir | Abacavir Sulfate | 22 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Efavirenz | Efavirenz | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pifeltro | Doravirine | 13 | suppressed |
| Atovaquone | Atovaquone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vivitrol | Naltrexone Microspheres | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Dronabinol | Dronabinol | 11 | suppressed |
| Edurant | Rilpivirine Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nevirapine Er | Nevirapine | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,648.73 · 18 records | ABBVIE INC. | MAVYRET, Vemlidy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error